These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18950514)

  • 1. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
    Lu Y; Yao HP; Wang MH
    J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
    Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
    Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic variant RON160 expression in breast cancer and its potential as a therapeutic target by small molecule tyrosine kinase inhibitor.
    Yao HP; Zhuang CM; Zhou YQ; Zeng JY; Zhang RW; Wang MH
    Curr Cancer Drug Targets; 2013 Jul; 13(6):686-97. PubMed ID: 23597200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
    Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
    Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
    Xu XM; Zhou YQ; Wang MH
    J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of RON differentially regulates claudin expression and localization: role of claudin-1 in RON-mediated epithelial cell motility.
    Zhang K; Yao HP; Wang MH
    Carcinogenesis; 2008 Mar; 29(3):552-9. PubMed ID: 18204077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
    Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
    Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RON and RONΔ160 promote gastric cancer cell proliferation, migration, and adaption to hypoxia via interaction with β-catenin.
    Zhou D; Huang L; Zhou Y; Wei T; Yang L; Li C
    Aging (Albany NY); 2019 May; 11(9):2735-2748. PubMed ID: 31085796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Catenin is required for Ron receptor-induced mammary tumorigenesis.
    Wagh PK; Gray JK; Zinser GM; Vasiliauskas J; James L; Monga SP; Waltz SE
    Oncogene; 2011 Aug; 30(34):3694-704. PubMed ID: 21423209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
    Camp ER; Yang A; Gray MJ; Fan F; Hamilton SR; Evans DB; Hooper AT; Pereira DS; Hicklin DJ; Ellis LM
    Cancer; 2007 Mar; 109(6):1030-9. PubMed ID: 17311308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
    Iwama A; Yamaguchi N; Suda T
    EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel variant of the RON receptor tyrosine kinase derived from colorectal carcinoma cells which lacks tyrosine phosphorylation but induces cell migration.
    Wang D; Lao WF; Kuang YY; Geng SM; Mo LJ; He C
    Exp Cell Res; 2012 Dec; 318(20):2548-58. PubMed ID: 22975341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis.
    Peace BE; Hughes MJ; Degen SJ; Waltz SE
    Oncogene; 2001 Sep; 20(43):6142-51. PubMed ID: 11593422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
    Lu Y; Yao HP; Wang MH
    Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.